We are live on ! Find out more
PVLA

Palvella Therapeutics
PVLA

98 hedge funds and large institutions have $96.9M invested in Palvella Therapeutics in 2019 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 27 increasing their positions, 31 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

127% more call options, than puts

Call options by funds: $693K | Put options by funds: $305K

36% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 14

5% more funds holding

Funds holding: 93 → 98 (+5)

0.02% more ownership

Funds ownership: 0.7% → 0.72% (+0.02%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

13% less repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 31

25% less capital invested

Capital invested by funds: $129M → $96.9M (-$31.9M)

Holders
98
Holders Change
+5
Holders Change %
+5.38%
% of All Funds
2.15%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
19
Increased
27
Reduced
31
Closed
14
Calls
$693K
Puts
$305K
Net Calls
+$388K
Net Calls Change
+$383K

Top Buyers

Rank Fund Capital Flow
1
ACM
Aquilo Capital Management
California
+$7.29M
2
BI
BVF Inc
California
+$6.75M
3
BlackRock
BlackRock
New York
+$4.39M
4
CS
Candriam SCA
Luxembourg
+$3.19M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$2.9M

Top Sellers

Rank Fund Capital Flow
1
NCM
Nantahala Capital Management
Connecticut
-$6.95M
2
Millennium Management
Millennium Management
New York
-$5.69M
3
American Century Companies
American Century Companies
Missouri
-$3.1M
4
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$1.7M
5
FI
Fosun International
China
-$1.62M
Name Holding Trade Value Shares
Change 		Change in
Stake
6CM
26
683 Capital Management
New York
$512K – – –
Citadel Advisors
27
Citadel Advisors
Florida
$440K -$148K -383 -19%
Jacobs Levy Equity Management
28
Jacobs Levy Equity Management
New Jersey
$425K -$178K -460 -23%
Bank of New York Mellon
29
Bank of New York Mellon
New York
$418K +$67.8K +175 +13%
Two Sigma Advisers
30
Two Sigma Advisers
New York
$397K -$17K -44 -3%
Charles Schwab
31
Charles Schwab
California
$396K +$94.1K +243 +20%
SIM
32
Spark Investment Management
New York
$395K – – –
SO
33
STRS Ohio
Ohio
$359K -$35.6K -92 -7%
Creative Planning
34
Creative Planning
Kansas
$327K +$33.7K +87 +8%
Massachusetts Financial Services
35
Massachusetts Financial Services
Massachusetts
$327K +$51.9K +134 +13%
HT
36
HAP Trading
New York
$317K +$450K +1,163 New
Wells Fargo
37
Wells Fargo
California
$315K +$16.3K +42 +4%
D.E. Shaw & Co
38
D.E. Shaw & Co
New York
$299K +$5.81K +15 +1%
California State Teachers Retirement System (CalSTRS)
39
California State Teachers Retirement System (CalSTRS)
California
$243K – – –
State of Wisconsin Investment Board
40
State of Wisconsin Investment Board
Wisconsin
$243K – – –
RJA
41
Raymond James & Associates
Florida
$233K +$24.4K +63 +8%
Mariner
42
Mariner
Kansas
$222K – – –
VF
43
Virtu Financial
New York
$221K +$313K +809 New
RhumbLine Advisers
44
RhumbLine Advisers
Massachusetts
$214K -$2.32K -6 -0.8%
RCG
45
Rock Creek Group
District of Columbia
$205K -$72.8K -188 -20%
Susquehanna International Group
46
Susquehanna International Group
Pennsylvania
$203K +$72K +186 +33%
RC
47
RBF Capital
California
$191K – – –
Barclays
48
Barclays
United Kingdom
$170K -$15.9K -41 -6%
GIP
49
Granite Investment Partners
California
$147K -$132K -341 -39%
AGM
50
Alpine Global Management
New York
$147K -$8.9K -23 -4%
1
2
3 4 5

PVLA Hedge Fund Activity: Q3 2019 in Review

98 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q3 2019, worth a combined $96.9M — down 25% from $129M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new PVLA positions and 14 closed out — a net gain of 5 holders — while 27 added to existing stakes and 31 trimmed.

The largest buyer was Aquilo Capital Management, adding an estimated $7.29M. The largest seller was Nantahala Capital Management, exiting entirely with an estimated $6.95M sold.

  • 98 institutional investors held Palvella Therapeutics (PVLA) as of Q3 2019, up from 93 in Q2 2019.
  • Funds reported $96.9M of Palvella Therapeutics stock for Q3 2019, down 25% quarter-over-quarter.
  • 19 funds opened new Palvella Therapeutics positions in Q3 2019 and 14 closed out, a net change of +5 holders.
  • The largest Palvella Therapeutics buyer in Q3 2019 was Aquilo Capital Management, an estimated $7.29M added.
  • The largest Palvella Therapeutics seller in Q3 2019 was Nantahala Capital Management, an estimated $6.95M sold.

Based on aggregated 13F filings for Q3 2019.